DK2959005T3 - Medicinsk anvendelse relateret til telomer forlængelse - Google Patents

Medicinsk anvendelse relateret til telomer forlængelse Download PDF

Info

Publication number
DK2959005T3
DK2959005T3 DK14754545.3T DK14754545T DK2959005T3 DK 2959005 T3 DK2959005 T3 DK 2959005T3 DK 14754545 T DK14754545 T DK 14754545T DK 2959005 T3 DK2959005 T3 DK 2959005T3
Authority
DK
Denmark
Prior art keywords
medical use
use related
telomere extension
telomere
extension
Prior art date
Application number
DK14754545.3T
Other languages
English (en)
Inventor
John Ramunas
Eduard Yakubov
Helen M Blau
John Cooke
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK2959005T3 publication Critical patent/DK2959005T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
DK14754545.3T 2013-02-22 2014-02-22 Medicinsk anvendelse relateret til telomer forlængelse DK2959005T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361768047P 2013-02-22 2013-02-22
PCT/US2014/017867 WO2014130909A1 (en) 2013-02-22 2014-02-22 Compounds, compositions, methods, and kits relating to telomere extension

Publications (1)

Publication Number Publication Date
DK2959005T3 true DK2959005T3 (da) 2022-01-03

Family

ID=51388399

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14754545.3T DK2959005T3 (da) 2013-02-22 2014-02-22 Medicinsk anvendelse relateret til telomer forlængelse

Country Status (20)

Country Link
US (5) US10525075B2 (da)
EP (2) EP2959005B1 (da)
JP (3) JP2016514953A (da)
CN (2) CN105164269A (da)
AU (1) AU2014218667A1 (da)
CA (1) CA2902237C (da)
CY (1) CY1125092T1 (da)
DK (1) DK2959005T3 (da)
ES (1) ES2901402T3 (da)
HK (1) HK1218934A1 (da)
HR (1) HRP20211842T1 (da)
HU (1) HUE056638T2 (da)
IL (2) IL240680B2 (da)
LT (1) LT2959005T (da)
PL (1) PL2959005T3 (da)
PT (1) PT2959005T (da)
RS (1) RS62824B1 (da)
RU (2) RU2022101438A (da)
SI (1) SI2959005T1 (da)
WO (1) WO2014130909A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013086008A1 (en) 2011-12-05 2013-06-13 Factor Bioscience Inc. Methods and products for transfecting cells
CN115927242A (zh) 2012-05-11 2023-04-07 珍白斯凯尔有限公司 具有抗炎活性的肽及其在制备抗炎组合物中的应用
WO2014010971A1 (ko) 2012-07-11 2014-01-16 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
EP3786298A1 (en) 2012-11-01 2021-03-03 Factor Bioscience Inc. Methods and products for expressing proteins in cells
IL240680B2 (en) 2013-02-22 2023-03-01 Univ Leland Stanford Junior Nucleic acids encoding telomerase reverse transcriptase, preparations containing them and their uses
JP6728049B2 (ja) 2013-10-30 2020-07-22 ザ キュレイターズ オブ ザ ユニバーシティ オブ ミズーリ 拡張性のある骨格筋系譜形成及び培養の方法
KR102314231B1 (ko) 2013-12-17 2021-10-19 주식회사 젬백스앤카엘 전립선 암 치료용 조성물
EP3099801B1 (en) 2014-01-31 2020-03-18 Factor Bioscience Inc. Synthetic rna for use in the treatment of dystrophic epidermolysis bullosa
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
TW201631152A (zh) 2014-12-29 2016-09-01 諾華公司 製造嵌合抗原受體－表現細胞之方法
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN107405380B (zh) * 2015-02-27 2021-04-20 珍白斯凯尔有限公司 用于预防听觉损伤的肽及其包含该肽的组合物
EP3283619B1 (en) 2015-04-17 2023-04-05 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
CA2990883A1 (en) * 2015-06-30 2017-01-05 Ethris Gmbh Atp-binding cassette family coding polyribonucleotides and formulations thereof
KR102638286B1 (ko) 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
CN108431021B (zh) * 2015-11-03 2021-09-07 珍白斯凯尔有限公司 具有神经元损失预防和再生效果的肽以及包含该肽的组合物
US20180360924A1 (en) * 2015-11-25 2018-12-20 The Methodist Hospital System Telomere extension and anti-inflammatory agents for cell regeneration
CN109328068A (zh) 2016-04-07 2019-02-12 珍白斯凯尔有限公司 具有增加端粒酶活性和延长端粒的效果的肽以及包含该肽的组合物
US11859232B2 (en) * 2016-06-19 2024-01-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Screening for chemotherapy resistance in human haploid cells
CA3033788A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US11976302B2 (en) 2017-05-06 2024-05-07 Upside Foods, Inc. Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure
WO2019014652A1 (en) 2017-07-13 2019-01-17 Memphis Meats, Inc. COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF CELL CULTURES USED IN FOOD PRODUCTION
KR20200069358A (ko) 2017-10-25 2020-06-16 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
BR112021003305A2 (pt) 2018-08-31 2021-05-25 Novartis Ag métodos para produzir células que expressam receptor de antígeno quimérico
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
US20210238564A1 (en) * 2018-09-06 2021-08-05 The Board Of Regents Of The University Of Texas System Telomerase holoenzyme complex and methods of use thereof
KR102209234B1 (ko) * 2018-10-02 2021-02-01 주식회사 스템온 세포의 텔로미어를 신장시키는 방법
JP7320302B2 (ja) * 2018-10-02 2023-08-03 ステムオン インコーポレーテッド 細胞のテロメアを伸長させる組成物およびその製造方法
US20220025352A1 (en) * 2018-10-02 2022-01-27 Stemon Inc. Method for extending telomere of cell
CN113710234A (zh) * 2019-02-08 2021-11-26 得克萨斯州大学系统董事会 用于治疗衰老相关疾病和年龄相关器官功能障碍的含端粒酶的外排体
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020223475A1 (en) * 2019-05-02 2020-11-05 Board Of Regents, The University Of Texas System Methods and compositions involving tert activating therapies
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
EP4065158A2 (en) 2019-11-26 2022-10-05 Novartis AG Chimeric antigen receptors binding bcma and cd19 and uses thereof
JP2023519078A (ja) * 2020-01-10 2023-05-10 アンドラニック アンドリュー アプリキャン， 目的の遺伝子の発現および／またはシグナル伝達経路の調節のためのナノ粒子
EP4106777A4 (en) * 2020-02-17 2024-03-27 Figene Llc TELOMER LENGTH MODULATION USING FIBROBLASS
MX2022010685A (es) 2020-02-27 2022-09-23 Novartis Ag Metodos de produccion de celulas que expresan receptores de antigeno quimericos.
CN116870195A (zh) * 2020-09-22 2023-10-13 浙江愈方生物科技有限公司 一种灭活性端粒酶、具有其的腺病毒和人造mRNA及应用
JP2024501388A (ja) * 2020-12-29 2024-01-11 リジュベネーション テクノロジーズ インク． Ｒｎａの送達のための組成物および方法
CA3215112A1 (en) * 2021-03-31 2022-10-06 Rejuvenation Technologies Inc. Compositions and methods for delivery of rna
WO2024056809A1 (en) 2022-09-15 2024-03-21 Novartis Ag Treatment of autoimmune disorders using chimeric antigen receptor therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686306A (en) 1992-05-13 1997-11-11 Board Of Regents, The University Of Texas System Methods and reagents for lengthening telomeres
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
IL129103A0 (en) 1996-10-01 2000-02-17 Geron Corp Human telomerase catalytic subunit and pharmaceutical compositions containing same
US8323975B2 (en) * 2002-01-04 2012-12-04 The Board Of Trustees Of The Leland Stanford Junior University Telomere-encoding synthetic DNA nanocircles, and their use for the elongation of telomere repeats
US7897752B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
MXPA06002660A (es) 2003-09-09 2006-09-04 Geron Corp Oligonucleotidos modificados para inhibicion de telomerasa.
DE102004035227A1 (de) * 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
EP2578685B1 (en) 2005-08-23 2019-04-17 The Trustees Of The University Of Pennsylvania Rna containing modified nucleosides and methods of use thereof
AU2006297394B9 (en) 2005-09-29 2013-09-19 Novartis Ag Receptacles and kits, such as for dry powder packaging
GB0720486D0 (en) 2007-10-19 2007-11-28 Univ Edinburgh Cationic lipids
US20110243957A1 (en) 2008-09-24 2011-10-06 University Of South Florida Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation
AU2010328310B2 (en) 2009-12-07 2015-05-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
RU2443777C2 (ru) * 2010-03-24 2012-02-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт клинической иммунологии Сибирского отделения РАМН Способ одномоментного определения длины теломер и количества делений популяции пролиферирующих клеток in vitro
CA3122219A1 (en) * 2010-04-16 2011-10-20 The Children's Hospital Corporation Sustained polypeptide expression from synthetic, modified rnas and uses thereof
WO2012009682A2 (en) 2010-07-15 2012-01-19 The Board Of Trustees Of The Leland Stanford Junior University Elastic substrates and methods of use in cell manipulation and culture
CN102433297A (zh) * 2011-10-14 2012-05-02 黄必录 延伸成体多能干细胞端粒的方法
WO2013086008A1 (en) 2011-12-05 2013-06-13 Factor Bioscience Inc. Methods and products for transfecting cells
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
IL240680B2 (en) 2013-02-22 2023-03-01 Univ Leland Stanford Junior Nucleic acids encoding telomerase reverse transcriptase, preparations containing them and their uses
JP6123561B2 (ja) 2013-08-08 2017-05-10 ソニー株式会社 発光素子及びその製造方法、並びに、表示装置

Also Published As

Publication number Publication date
US20200215095A1 (en) 2020-07-09
PL2959005T3 (pl) 2022-01-31
CA2902237A1 (en) 2014-08-28
JP7103653B2 (ja) 2022-07-20
EP2959005A1 (en) 2015-12-30
JP2022141694A (ja) 2022-09-29
JP2019201651A (ja) 2019-11-28
RU2022101438A (ru) 2022-02-11
US20140242154A1 (en) 2014-08-28
IL240680B2 (en) 2023-03-01
JP7486836B2 (ja) 2024-05-20
PT2959005T (pt) 2021-12-30
HRP20211842T1 (hr) 2022-03-04
LT2959005T (lt) 2022-01-25
US10525075B2 (en) 2020-01-07
CA2902237C (en) 2024-02-13
RS62824B1 (sr) 2022-02-28
US20140242155A1 (en) 2014-08-28
IL240680A0 (en) 2015-10-29
WO2014130909A1 (en) 2014-08-28
CN105164269A (zh) 2015-12-16
IL296870A (en) 2022-11-01
SI2959005T1 (sl) 2022-01-31
HUE056638T2 (hu) 2022-02-28
US20200215094A1 (en) 2020-07-09
US11872243B2 (en) 2024-01-16
EP2959005A4 (en) 2016-12-21
JP2016514953A (ja) 2016-05-26
RU2015140125A (ru) 2017-03-28
CY1125092T1 (el) 2023-03-24
CN117838716A (zh) 2024-04-09
EP3988112A1 (en) 2022-04-27
US20200281959A1 (en) 2020-09-10
US11007210B2 (en) 2021-05-18
EP2959005B1 (en) 2021-10-06
RU2015140125A3 (da) 2018-02-28
HK1218934A1 (zh) 2017-03-17
AU2014218667A1 (en) 2015-10-08
RU2766120C2 (ru) 2022-02-08
ES2901402T3 (es) 2022-03-22
IL240680B (en) 2022-11-01

Similar Documents

Publication Publication Date Title
DK2959005T3 (da) Medicinsk anvendelse relateret til telomer forlængelse
DK2941163T3 (da) Hudrenser
BR302014002091S1 (pt) Configuraçao aplicada em equipamento médico
DK3053119T3 (da) Papirløs anvendelse
BR302013004392S1 (pt) Configuração aplicada emmetal sanitário
BR302014002089S1 (pt) Configuração aplicada em equipamento médico
BR112016010669A2 (pt) composição desinfetante
DK3019099T3 (da) Elektrokirurgisk slynge
DK3027750T3 (da) Biokatalytisk sammensætning
DK2992104T3 (da) Fremgangsmåde til ekspression
BR302013005133S1 (pt) Configuração aplicada em alça de cateter
DK2956010T4 (da) Fedtsammensætning
FR3001392B1 (fr) Composition dermatologique amelioree
FI20130360A (fi) Mammografialaite
DK3089778T3 (da) Ballonkateter
CL2014001168S1 (es) Tobogan telescopico
DE112013006363A5 (de) Endoskop
DE112014003129A5 (de) Medizinischer Clip
FI20136034A (fi) Sauna
UA29452S (uk) Тостер
ES1078780Y (es) Fregona de escurrido podal
UA28339S (uk) Медичний пристрій-шприц
UA28338S (uk) Медичний пристрій-шприц
DK3082855T3 (da) Sammensætning
FI10036U1 (fi) Potilasalusta